CTLA4 and non-small cell lung carcinoma: (2) During treatment with the other two drugs, anti-CTLA-4 and anti-MUC1, smokers are more likely to respond better than the non-smokers in the treatment of NSCLC patients (Supplementary Material, Part D, Part I).